tickdelta
tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

EWEdwards Lifesciences

Health care · Medical Devices · NYSE
EW quote by TradingView
Compare with peers → Embed
FY2025 at a glance

Sales up 11.5%, free cash flow up to $1.3B

XBRL, from each 10-K
RevenueStatements ↓
$6.1B
from $5.4B in FY2024
FY2016FY2025
Net incomeStatements ↓
$1.1B
from $4.2B in FY2024
FY2016FY2025
Free cash flowStatements ↓
$1.3B
from $289.9M in FY2024
FY2016FY2025
EPS (diluted)Statements ↓
$1.83
from $6.97 in FY2024
FY2016FY2025
Operating marginStatements ↓
20.8%
from 25.3% in FY2024
FY2016FY2025
Total debtStatements ↓
$598.3M
from $597.7M in FY2024
FY2016FY2025
Price and key numbers

The latest figures

All key numbers (41, from the latest 10-K and 10-Q) From EDGAR
EPS (ttm)1.77Sales (ttm)6.7BNet income (ttm)1.0BSales growth+11.5%EPS growth-73.7%Sales Q/Q+10.5%
Free cash flow1.4BGross margin78.0%Oper. margin21.6%Net margin15.3%FCF margin21.3%ROE9.4%
ROA7.2%R&D / sales17.8%Dividend-Debt/Eq0.06Curr. ratio4.60Cash3.1B
Op. cash flow (ttm)1.7BEBITDA1.4BEBITDA margin23.4%Net debt-2.5BQuick ratio3.88Interest cover61.97
ROIC9.2%Tax rate17.0%Stock pay / sales2.6%Shares out.575.0MShares Y/Y-2.3%Book / share18.89
Cash / share5.41Sales / share11.61Asset turnover0.47Inventory turns1.18Days sales out.40Sales 3Y CAGR+10.8%
Sales 5Y CAGR+6.7%EPS 3Y CAGR-9.1%EPS 5Y CAGR+7.1%Employees16,000Sales / employee417K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Changes in the numbers

FY2025 against FY2024
  • Free cash flow rose 361%$289.9M → $1.3B · Cash from operations − capital expenditure · 10-K ↗
  • Operating margin narrowed to 20.8%25.3% → 20.8% · Operating income / revenue · 10-K ↗
What management wrote about it → · Every company →

EW against Health care peers

Ten years, side by side → · All 60 →
GrowthProfitBalanceCleanInsiders
EWPeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.

Sales growth
+11.5%14th of 60 · median +7.1%
Net margin
15.3%20th of 60 · median 9.6%
Return on equity
9.4%34th of 54 · median 13.1%
Free cash flow margin
21.3%15th of 56 · median 15.5%
Debt / equity (less is better)
0.061st of 49 · median 0.66
EW and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthGross marginNet marginROEFCF marginDebt / equity
EW Edwards Lifesciences$6.7B +11.5%78.0%15.3%9.4%21.3%0.06
SOLV Solventum$8.2B +0.9%54.8%1.9%3.2%0.0%0.95
A Agilent Technologies$7.4B +6.7%53.8%19.5%19.6%17.2%0.54
STE Steris$6.2B +8.7%44.6%13.4%11.4%15.2%0.26
INCY Incyte$6.0B +21.2%92.7%6.7%7.1%--
RMD ResMed$5.7B +9.9%61.1%27.8%26.8%28.1%0.07
Where each dollar goes

From $5.2B of sales to $1.5B of profit

FY2021, from the 10-K income statement
Revenue to Gross profit: $4.0BRevenue to Cost of revenue: $1.2BGross profit to Operating profit: $1.7BGross profit to Operating expenses: $2.3BOperating profit to Net profit: $1.5BOperating profit to Tax & other: $187.2MOperating expenses to R&D: $903.1MOperating expenses to Sales, admin & other: $1.4B Revenue: $5.2B Revenue$5.2B +19% Y/Y Gross profit: $4.0B · 76% margin Gross profit$4.0B76% margin +21% Y/Y Cost of revenue: $1.2B · 24% of revenue Cost of revenue$1.2B24% of revenue Operating profit: $1.7B · 32% margin Operating profit$1.7B32% margin +88% Y/Y Operating expenses: $2.3B · 44% of revenue Operating expenses$2.3B44% of revenue Net profit: $1.5B · 29% margin Net profit$1.5B29% margin +83% Y/Y Tax & other: $187.2M · 4% of revenue Tax & other$187.2M4% of revenue R&D: $903.1M · 17% of revenue R&D$903.1M17% of revenue Sales, admin & other: $1.4B · 27% of revenue Sales, admin & other$1.4B27% of revenue

Swipe sideways for the whole flow →

From $4.5B of sales to $1.5B of profit

FY2022, from the 10-K income statement and revenue by product
Transcatheter Aortic Valve Replacement to Revenue: $3.5BSurgical Structural Heart to Revenue: $829.7MTranscatheter Mitral and Tricuspid Therapies to Revenue: $116.1MRevenue to Gross profit: $3.7BRevenue to Cost of revenue: $723.7MGross profit to Operating profit: $1.5BGross profit to Operating expenses: $2.2BOperating profit to Net profit: $1.3BOperating profit to Tax: $195.5MOther income to Net profit: $219.0MOperating expenses to R&D: $843.6MOperating expenses to SG&A: $1.4B Transcatheter Aortic Valve Replacement: $3.5B · 79% Transcatheter Aortic Va…$3.5B79% Surgical Structural Heart: $829.7M · 19% Surgical Structural Hea…$829.7M19% Transcatheter Mitral and Tricuspid Therapies: $116.1M · 3% Transcatheter Mitral an…$116.1M3% Revenue: $4.5B Revenue$4.5B −15% Y/Y Gross profit: $3.7B · 84% margin Gross profit$3.7B84% margin −6% Y/Y Cost of revenue: $723.7M · 16% of revenue Cost of revenue$723.7M16% of revenue Operating profit: $1.5B · 34% margin Operating profit$1.5B34% margin −11% Y/Y Other income: $219.0M · 5% of revenue Other income$219.0M5% of revenue Operating expenses: $2.2B · 50% of revenue Operating expenses$2.2B50% of revenue Net profit: $1.5B · 34% margin Net profit$1.5B34% margin +1% Y/Y Tax: $195.5M · 4% of revenue Tax$195.5M4% of revenue R&D: $843.6M · 19% of revenue R&D$843.6M19% of revenue SG&A: $1.4B · 31% of revenue SG&A$1.4B31% of revenue

Swipe sideways for the whole flow →

From $5.0B of sales to $1.4B of profit

FY2023, from the 10-K income statement and revenue by product
Transcatheter Aortic Valve Replacement to Revenue: $3.9BSurgical Structural Heart to Revenue: $932.6MTranscatheter Mitral and Tricuspid Therapies to Revenue: $197.6MRevenue to Gross profit: $4.0BRevenue to Cost of revenue: $978.4MGross profit to Operating profit: $1.3BGross profit to Operating expenses: $2.7BOperating profit to Net profit: $1.2BOperating profit to Tax: $152.4MOther income to Net profit: $245.9MOperating expenses to R&D: $962.9MOperating expenses to Sales, admin & other: $1.8B Transcatheter Aortic Valve Replacement: $3.9B · 77% Transcatheter Aortic Va…$3.9B77% Surgical Structural Heart: $932.6M · 19% Surgical Structural Hea…$932.6M19% Transcatheter Mitral and Tricuspid Therapies: $197.6M · 4% Transcatheter Mitral an…$197.6M4% Revenue: $5.0B Revenue$5.0B +12% Y/Y Gross profit: $4.0B · 80% margin Gross profit$4.0B80% margin +8% Y/Y Cost of revenue: $978.4M · 20% of revenue Cost of revenue$978.4M20% of revenue Operating profit: $1.3B · 26% margin Operating profit$1.3B26% margin −13% Y/Y Other income: $245.9M · 5% of revenue Other income$245.9M5% of revenue Operating expenses: $2.7B · 54% of revenue Operating expenses$2.7B54% of revenue Net profit: $1.4B · 28% margin Net profit$1.4B28% margin −8% Y/Y Tax: $152.4M · 3% of revenue Tax$152.4M3% of revenue R&D: $962.9M · 19% of revenue R&D$962.9M19% of revenue Sales, admin & other: $1.8B · 35% of revenue Sales, admin & other$1.8B35% of revenue

Swipe sideways for the whole flow →

From $5.4B of sales to $4.2B of profit

FY2024, from the 10-K income statement and revenue by product
Transcatheter Aortic Valve Replacement to Revenue: $4.1BSurgical Structural Heart to Revenue: $981.3MTranscatheter Mitral and Tricuspid Therapies to Revenue: $352.1MRevenue to Gross profit: $4.3BRevenue to Cost of revenue: $1.1BGross profit to Operating profit: $1.4BGross profit to Operating expenses: $2.9BOperating profit to Net profit: $1.2BOperating profit to Tax: $152.1MOther income to Net profit: $2.9BOperating expenses to R&D: $1.1BOperating expenses to Sales, admin & other: $1.9B Transcatheter Aortic Valve Replacement: $4.1B · 75% Transcatheter Aortic Va…$4.1B75% Surgical Structural Heart: $981.3M · 18% Surgical Structural Hea…$981.3M18% Transcatheter Mitral and Tricuspid Therapies: $352.1M · 6% Transcatheter Mitral an…$352.1M6% Revenue: $5.4B Revenue$5.4B +9% Y/Y Gross profit: $4.3B · 79% margin Gross profit$4.3B79% margin +7% Y/Y Cost of revenue: $1.1B · 21% of revenue Cost of revenue$1.1B21% of revenue Operating profit: $1.4B · 25% margin Operating profit$1.4B25% margin +5% Y/Y Other income: $2.9B · 54% of revenue Other income$2.9B54% of revenue Operating expenses: $2.9B · 54% of revenue Operating expenses$2.9B54% of revenue Net profit: $4.2B · 77% margin Net profit$4.2B77% margin +198% Y/Y Tax: $152.1M · 3% of revenue Tax$152.1M3% of revenue R&D: $1.1B · 19% of revenue R&D$1.1B19% of revenue Sales, admin & other: $1.9B · 35% of revenue Sales, admin & other$1.9B35% of revenue

Swipe sideways for the whole flow →

From $6.1B of sales to $1.1B of profit

FY2025, from the 10-K income statement and revenue by product
Transcatheter Aortic Valve Replacement to Revenue: $4.5BSurgical Structural Heart to Revenue: $1.0BTranscatheter Mitral and Tricuspid Therapies to Revenue: $550.6MRevenue to Gross profit: $4.7BRevenue to Cost of revenue: $1.3BGross profit to Operating profit: $1.3BGross profit to Operating expenses: $3.5BOperating profit to Net profit: $1.1BOperating profit to Tax & other: $190.7MOperating expenses to R&D: $1.1BOperating expenses to Sales, admin & other: $2.4B Transcatheter Aortic Valve Replacement: $4.5B · 74% Transcatheter Aortic Va…$4.5B74% Surgical Structural Heart: $1.0B · 17% Surgical Structural Hea…$1.0B17% Transcatheter Mitral and Tricuspid Therapies: $550.6M · 9% Transcatheter Mitral an…$550.6M9% Revenue: $6.1B Revenue$6.1B +12% Y/Y Gross profit: $4.7B · 78% margin Gross profit$4.7B78% margin +10% Y/Y Cost of revenue: $1.3B · 22% of revenue Cost of revenue$1.3B22% of revenue Operating profit: $1.3B · 21% margin Operating profit$1.3B21% margin −8% Y/Y Operating expenses: $3.5B · 57% of revenue Operating expenses$3.5B57% of revenue Net profit: $1.1B · 18% margin Net profit$1.1B18% margin −74% Y/Y Tax & other: $190.7M · 3% of revenue Tax & other$190.7M3% of revenue R&D: $1.1B · 18% of revenue R&D$1.1B18% of revenue Sales, admin & other: $2.4B · 39% of revenue Sales, admin & other$2.4B39% of revenue

Swipe sideways for the whole flow →

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax, less other income
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →

Profitability

3 of 4
  • ✓
    Net margin above the peer median15.3% vs 9.6%
  • ✓
    Gross margin up over 5 years75.4% → 78.0%
  • !
    Return on equity below 15%9.4%
  • ✓
    A profit in every one of 10 years
Net margin, FY2016 to FY2025: 19.2% → 17.7%

Balance sheet

4 of 4
  • ✓
    Interest covered more than 5 timesOperating income is 62.0× interest expense
  • ✓
    Debt smaller than equityDebt / equity 0.06 on the latest balance sheet (peer median 0.66)
  • ✓
    Current assets cover current liabilitiesCurrent ratio 4.60
  • ✓
    More cash than debtNet cash $3.8B
Debt / equity at each year end, FY2016 to FY2025: 0.31 → 0.06

Cash and shareholders

3 of 3
  • ✓
    Free cash flow positive in every one of 10 years$1.3B last year
  • ✓
    Share count down over 5 years−7.3%
  • ✓
    Cash from operations above net income$1.6B vs $1.1B
Free cash flow, FY2016 to FY2025: 528.3M → 1.3B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Revenue and net income, FY2016 to FY2025

Revenue 6.1B Net income 1.1B
FY2016 revenue 3.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001099800-19-000004 FY2016 net income 569.5M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001099800-19-000004 3.0B FY2016 FY2017 revenue 3.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001099800-20-000005 FY2017 net income 583.6M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001099800-20-000005 3.4B FY2017 FY2018 revenue 3.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001099800-21-000007 FY2018 net income 722.2M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001099800-21-000007 3.7B FY2018 FY2019 revenue 4.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001099800-22-000005 FY2019 net income 1.0B · NetIncomeLossAvailableToCommonStockholdersBasic, 0001099800-22-000005 4.3B FY2019 FY2020 revenue 4.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001099800-23-000005 FY2020 net income 823.4M · NetIncomeLossAvailableToCommonStockholdersBasic, 0001099800-23-000005 4.4B FY2020 FY2021 revenue 5.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001099800-24-000004 FY2021 net income 1.5B · NetIncomeLoss, 0001099800-24-000004 5.2B FY2021 FY2022 revenue 4.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001099800-25-000005 FY2022 net income 1.5B · NetIncomeLoss, 0001099800-25-000005 4.5B FY2022 FY2023 revenue 5.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001099800-26-000009 FY2023 net income 1.4B · NetIncomeLoss, 0001099800-26-000009 5.0B FY2023 FY2024 revenue 5.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001099800-26-000009 FY2024 net income 4.2B · NetIncomeLoss, 0001099800-26-000009 5.4B FY2024 FY2025 revenue 6.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001099800-26-000009 FY2025 net income 1.1B · NetIncomeLoss, 0001099800-26-000009 6.1B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

Statements

Income statement, balance sheet and cash flow

XBRL, each 10-K and 10-Q

EW's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly
Revenue6.1B
FY2016: 3.0BFY2017: 3.4BFY2018: 3.7BFY2019: 4.3BFY2020: 4.4BFY2021: 5.2BFY2022: 4.5BFY2023: 5.0BFY2024: 5.4BFY2025: 6.1B FY2017FY2019FY2021FY2023FY2025
Net income1.1B
FY2016: 569.5MFY2017: 583.6MFY2018: 722.2MFY2019: 1.0BFY2020: 823.4MFY2021: 1.5BFY2022: 1.5BFY2023: 1.4BFY2024: 4.2BFY2025: 1.1B FY2017FY2019FY2021FY2023FY2025
Free cash flow1.3B
FY2016: 528.3MFY2017: 832.6MFY2018: 688.0MFY2019: 928.5MFY2020: 647.3MFY2021: 1.4BFY2022: 973.6MFY2023: 642.8MFY2024: 289.9MFY2025: 1.3B FY2017FY2019FY2021FY2023FY2025
EPS (diluted)1.83
FY2016: 0.87FY2017: 0.90FY2018: 1.13FY2019: 1.64FY2020: 1.30FY2021: 2.38FY2022: 2.44FY2023: 2.30FY2024: 6.97FY2025: 1.83 FY2017FY2019FY2021FY2023FY2025
Diluted shares585.8M
FY2016: 653.4MFY2017: 647.7MFY2018: 640.9MFY2019: 636.7MFY2020: 631.9MFY2021: 631.2MFY2022: 624.2MFY2023: 609.4MFY2024: 599.3MFY2025: 585.8M FY2017FY2019FY2021FY2023FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
United States 3.5B58.4% +10.5%
Europe 1.5B25.0% +14.8%
Rest Of World 652.3M10.8% +14.0%
Japan 354.7M5.8% +4.4%

10-K 0001099800-26-000009, segment and revenue notes (XBRL).

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Transcatheter Aortic Valve Replacement 4.5B74.0% +9.3%
Surgical Structural Heart 1.0B17.0% +4.9%
Transcatheter Mitral and Tricuspid Therapies 550.6M9.1% +56.4%

10-K 0001099800-26-000009, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue3.0B3.4B3.7B4.3B4.4B5.2B4.5B5.0B5.4B6.1B
Cost of revenue797.4M875.3M939.4M1.1B1.1B1.2B723.7M978.4M1.1B1.3B
Gross profit2.2B2.6B2.8B3.2B3.3B4.0B3.7B4.0B4.3B4.7B
R&D442.2M552.6M622.2M752.7M760.7M903.1M843.6M962.9M1.1B1.1B
SG&A904.7M990.8M1.1B1.2B1.2B1.5B1.4B1.6B1.8B2.1B
Operating income751.2M1.1B748.2M1.1B897.6M1.7B1.5B1.3B1.4B1.3B
Interest expense19.2M23.2M29.9M20.7M15.8M18.4M19.2M17.6M19.8M20.4M
Pretax income737.9M1.0B761.4M1.2B916.7M1.7B1.5B1.4B1.5B1.3B
Income tax168.4M451.3M39.2M119.6M93.3M198.9M195.5M152.4M152.1M216.9M
Net income569.5M583.6M722.2M1.0B823.4M1.5B1.5B1.4B4.2B1.1B
EPS (diluted)0.870.901.131.641.302.382.442.306.971.83
Diluted shares653.4M647.7M640.9M636.7M631.9M631.2M624.2M609.4M599.3M585.8M
Depreciation & amortization71.2M81.9M77.4M89.3M107.2M134.8M139.6M144.9M155.2M156.6M
EBITDA822.4M1.2B825.6M1.2B1.0B1.8B1.6B1.5B1.5B1.4B
Gross margin73.1%74.5%74.8%74.4%75.4%76.1%83.8%80.5%79.5%78.0%
Operating margin25.3%31.7%20.1%26.4%20.5%32.3%33.6%26.1%25.3%20.8%
Net margin19.2%17.0%19.4%24.1%18.8%28.7%34.1%28.0%76.7%17.7%
Revenue growth-+15.9%+8.4%+16.8%+0.9%+19.3%-14.7%+12.2%+8.6%+11.5%
EPS growth-+3.4%+25.6%+45.1%-20.7%+83.1%+2.5%-5.7%+203%-73.7%

Balance sheet

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash930.1M818.3M714.1M1.2B1.2B862.8M769.0M1.1B3.0B2.9B
Short-term investments341.0M519.2M242.4M337.8M219.4M604.0M446.3M500.5M930.7M1.3B
Receivables365.5M438.7M456.9M543.6M514.6M582.2M643.0M771.5M609.1M659.6M
Inventory396.6M554.9M607.0M640.9M802.3M726.7M875.5M903.5M1.1B1.1B
Current assets2.2B2.5B2.3B3.0B3.1B3.2B3.1B4.0B6.3B6.7B
Property & equipment580.0M679.7M867.5M1.1B1.4B1.5B1.6B1.6B1.7B1.8B
Goodwill626.1M1.1B1.1B1.2B1.2B1.2B1.1B1.1B1.8B1.8B
Total assets4.5B5.7B5.3B6.5B7.2B8.5B8.3B9.4B13.1B13.7B
Accounts payable97.1M116.6M134.0M180.4M196.5M204.5M201.9M186.6M197.4M227.5M
Current liabilities532.5M1.4B876.6M902.4M893.9M1.0B1.0B1.2B1.5B1.8B
Total debt822.3M1.0B593.8M594.4M595.0M595.7M596.3M597.0M597.7M598.3M
Total liabilities----2.7B2.7B2.5B2.6B3.0B3.4B
Shareholders' equity2.6B3.0B3.1B4.1B4.6B5.8B5.8B6.7B10.0B10.3B
Retained earnings3.9B2.0B2.7B3.7B4.6B6.1B7.6B9.0B13.2B14.2B

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow704.4M1.0B926.7M1.2B1.1B1.7B1.2B895.8M542.3M1.6B
Capital spending176.1M168.1M238.7M254.4M407.0M325.8M244.6M253.0M252.4M260.2M
Free cash flow528.3M832.6M688.0M928.5M647.3M1.4B973.6M642.8M289.9M1.3B
Stock-based pay (added back)56.9M61.6M71.0M81.3M92.6M109.3M126.8M139.4M162.3M158.1M
Buybacks662.3M763.3M795.5M263.3M625.4M512.8M1.7B879.6M1.2B893.4M
Acquisitions0192.9M0100.2M00----
Debt raised253.5M994.7M688.0M18.9M16.2M5.2M00--
Investing cash flow-211.7M-647.2M76.7M-595.8M-531.1M-1.7B252.3M173.8M2.3B-712.9M
Financing cash flow-268.5M-473.2M-1.1B-115.6M-486.9M-356.3M-1.6B-711.0M-983.0M-956.8M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)56.9M61.6M71.0M81.3M92.6M109.3M126.8M139.4M162.3M158.1M
Stock-based pay / revenue1.9%1.8%1.9%1.9%2.1%2.1%2.8%2.8%3.0%2.6%
Operating lease cost--27.0M27.9M30.5M29.7M25.6M26.9M28.1M29.3M
Operating lease cash paid--028.6M29.7M31.9M25.0M25.7M28.0M29.3M
Right-of-use assets---80.1M94.2M92.1M92.3M84.4M98.2M102.7M
Operating lease liabilities---84.4M99.9M94.6M95.0M88.1M102.3M107.1M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Next Peers in numbers →